TQH2722 + mometasone furoate

TQH2722 + mometasone furoate is a combination therapy evaluated in clinical trials for **seasonal allergic rhinitis** in patients who are not responsive to standard treatments. **TQH2722** is a humanized monoclonal antibody that targets interleukin 4 receptor alpha (IL-4Rα), leading to dual blockade of IL-4 and IL-13 signaling, thereby inhibiting the T-helper cell type 2 immune pathway linked to Th2-mediated diseases such as atopic dermatitis, asthma, and chronic sinusitis[1][2][3][4]. **Mometasone furoate** is a well-established synthetic corticosteroid with potent anti-inflammatory properties, administered via nasal spray as a standard treatment for allergic rhinitis. The combination is tested to evaluate added efficacy and immune modulation compared to standard of care. In ongoing studies, all patients receive mometasone furoate nasal spray and loratadine in the background, with TQH2722 or placebo as the investigational intervention[5][6].

Other names

TQH-2722 + mometasone furoate